A preclinical study showed that double blockade of LAG-3 and PD-1 with TSR-033 and TSR-042 increased the total amount and proliferation rate of T cells in model mice harboring humanized NSCLC tumors compared to the effects of TSR-042 monotherapy; these results are consistent with increased antitumor efficacy [165]. Here, PDCD1 is linked to non-small cell lung carcinoma.